400 mg daily, given in two divided doses, as above.
This dosage may be increased to 800 mg daily, if necessary, and may sometimes be reduced to as low as 200 mg daily after the blood urate level has been controlled.
Treatment should be continued without interruptian even in the presence of acute exacerbations, which can be concomitantly treated with phenylbutazone or colchicine.Patients previously controlled with other uricosuric therapy may be transferred to Anturane at full maintenance dosage.
Patients with an active peptic ulcer or symptoms of gastrointestinal inflammation or ulceration should not receive the drug.The drug is contraindicated in patients with a history or the presence of: Hypersensitivity to phenylbutazone or other pyrazoles Blood dyscrasias
Studies on the teratogenicity of pyrazole compounds in animals have yielded inconclusive results.Up to the present time, however, there have been no reported cases of human congenital malformation proved to be due to the use of the drug. It is suggested that Anturane be used with caution in pregnant women, weighing the potential risks against the possible benefits.